EQL Pharma is a generics- and speciality pharma company, dedicated to providing cost efficient pharmaceuticals for the Nordic markets. This is accomplished with the highest quality standards and streamlined logistic solutions.
The Nomination Committee for the Annual General Meeting in 2017
2017-01-23 In accordance with a resolution from the 2016 Annual General Meeting the Nomination Committee shall consist of the Chairman of the Board and one representative for each of the three largest shareholders in terms of voting rights at the end of…
EQL Pharma strengthens its organization with Alexander Brising, New Business Development Director
EQL Pharma has recruited Alexander Brising as head of business development at EQL Pharma. He joined the company in mid-November 2016. Alexander Brising will lead the work to identify new products for in-licensing or in-house development and thus strengthen an…
Zonisamid EQL Pharma now approved in Denmark
The medical product Zonisamid EQL Pharma has now been approved for sale by the Danish Medicines Agency. Zonisamid EQL Pharma is an anticonvulsant being used in the treatment of epilepsy. The name of the original product is Zonegran (Eisai Limited).…
- View all press releases